Showing 771-780 of 839 results for "".
- Cedars-Sinai Analysis Evaluates How Retinal Changes Correspond to Cognitive Changes in Alzheimer’s Diseasehttps://modernod.com/news/new-insights-eye-damage-in-alzheimers-disease-patients/2481455/Cedars-Sinai investigators have produced an analysis evaluating how retinal changes correspond to brain and cognitive changes in Alzheimer’s disease patients. Investigators looked at retinal and brain tissue samples collected over 14 years from 86 human donors—the
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- Verana Health Study of Patients with Dry AMD Published in International Ophthalmologyhttps://modernod.com/news/verana-health-study-of-patients-with-dry-amd-published-in-international-ophthalmology/2481301/Verana Health—a digital health company elevating quality in real-world data—announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.